Cabaletta Bio
Cabaletta Bio is a biotechnology company based in Philadelphia, PA, specializing in engineered T cell therapies for autoimmune diseases using its proprietary CABA platform.
Company Overview
Cabaletta Bio is a biotechnology company focused on developing engineered T cell therapies specifically for autoimmune diseases. The company is headquartered in Philadelphia, PA, and leverages advanced technology through its CABA® platform to create innovative cell therapy products.
Lead Product Candidate: CABA-201
Cabaletta Bio's lead product candidate is CABA-201, a CD19-CAR T cell therapy. This treatment is being evaluated for its efficacy in treating autoimmune diseases such as lupus, myositis, systemic sclerosis, and generalized myasthenia gravis. CABA-201 has also received FDA Orphan Drug Designation for its potential in treating systemic sclerosis.
CABA® Platform Technology
The CABA® platform is central to Cabaletta Bio's strategy for developing cell therapy products. This proprietary technology is designed to engineer T cells that can precisely target and treat autoimmune diseases, offering potential new treatment avenues for conditions that currently have limited options.
RESET™ Clinical Trials
Cabaletta Bio is conducting RESET™ clinical trials to evaluate the safety and efficacy of CABA-201 in treating multiple autoimmune diseases. The trials are being carried out for conditions such as lupus, myositis, systemic sclerosis, and generalized myasthenia gravis. The outcomes of these trials could open new pathways for the treatment of these conditions.
Financial Status
As of December 31, 2023, Cabaletta Bio has $241.2 million in cash, cash equivalents, and short-term investments, providing a cash runway into the first half of 2026. This financial stability supports their ongoing research and development efforts, including clinical trials and other operational activities.